131 related articles for article (PubMed ID: 23714731)
1. A neu view of invasive lobular breast cancer.
Bose R
Clin Cancer Res; 2013 Jul; 19(13):3331-3. PubMed ID: 23714731
[TBL] [Abstract][Full Text] [Related]
2. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
[TBL] [Abstract][Full Text] [Related]
3. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
[TBL] [Abstract][Full Text] [Related]
4. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features.
Ding Q; Chen H; Lim B; Damodaran S; Chen W; Tripathy D; Piha-Paul S; Luthra R; Meric-Bernstam F; Sahin AA
Hum Pathol; 2019 Oct; 92():32-38. PubMed ID: 31351155
[TBL] [Abstract][Full Text] [Related]
5. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
[TBL] [Abstract][Full Text] [Related]
6. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
7. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer.
Rosenthal SI; Depowski PL; Sheehan CE; Ross JS
Appl Immunohistochem Mol Morphol; 2002 Mar; 10(1):40-6. PubMed ID: 11893034
[TBL] [Abstract][Full Text] [Related]
8. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
9. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
Lien HC; Chen YL; Juang YL; Jeng YM
Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
[TBL] [Abstract][Full Text] [Related]
10. The uncharted role of HER2 mutant alleles in breast cancer.
Kalra R; Lim B; Ellis MJ; Kavuri SM
Oncotarget; 2023 Oct; 14():904-907. PubMed ID: 37921670
[TBL] [Abstract][Full Text] [Related]
11. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
12. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
13. Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast.
Yoder BJ; Wilkinson EJ; Massoll NA
Breast J; 2007; 13(2):172-9. PubMed ID: 17319859
[TBL] [Abstract][Full Text] [Related]
14. CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk.
Lei H; Sjöberg-Margolin S; Salahshor S; Werelius B; Jandáková E; Hemminki K; Lindblom A; Vorechovský I
Int J Cancer; 2002 Mar; 98(2):199-204. PubMed ID: 11857408
[TBL] [Abstract][Full Text] [Related]
15. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
16. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer?
Cleton-Jansen AM
Breast Cancer Res; 2002; 4(1):5-8. PubMed ID: 11879552
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.
De Leeuw WJ; Berx G; Vos CB; Peterse JL; Van de Vijver MJ; Litvinov S; Van Roy F; Cornelisse CJ; Cleton-Jansen AM
J Pathol; 1997 Dec; 183(4):404-11. PubMed ID: 9496256
[TBL] [Abstract][Full Text] [Related]
18. The role of E-cadherin in low-grade ductal breast tumourigenesis.
Roylance R; Droufakou S; Gorman P; Gillett C; Hart IR; Hanby A; Tomlinson I
J Pathol; 2003 May; 200(1):53-8. PubMed ID: 12692841
[TBL] [Abstract][Full Text] [Related]
19. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
[TBL] [Abstract][Full Text] [Related]
20. Collective Wisdom: Lobular Carcinoma of the Breast.
Sledge GW; Chagpar A; Perou C
Am Soc Clin Oncol Educ Book; 2016; 35():18-21. PubMed ID: 27249682
[No Abstract] [Full Text] [Related]
[Next] [New Search]
